Rosiglitazone in Type 2 diabetes mellitus: an evaluation in British Indo-Asian patients.

@article{Barnett2003RosiglitazoneIT,
  title={Rosiglitazone in Type 2 diabetes mellitus: an evaluation in British Indo-Asian patients.},
  author={Anthony Barnett and Peter J. Grant and Graham A. Hitman and Hugh M Mather and Moo Kho Pawa and Lindsay Robertson and A Trelfa},
  journal={Diabetic medicine : a journal of the British Diabetic Association},
  year={2003},
  volume={20 5},
  pages={387-93}
}
AIMS To evaluate the effectiveness of rosiglitazone in reducing hyperglycaemia in patients with Type 2 diabetes mellitus (DM) of Indo-Asian origin taking concurrent sulphonylurea therapy. METHODS A randomized, double-blind, placebo-controlled study of 26 weeks' duration at 31 primary and secondary care centres in areas of the UK with a high Indo-Asian population, including 177 patients aged 28-78 years. Rosiglitazone 8 mg/day or matching placebo was added to existing sulphonylurea therapy… CONTINUE READING

Similar Papers

Loading similar papers…